Article
Impact of genotypic diversity on selection of subtype-specific drug resistance profiles during raltegravir-based therapy in individuals infected with B and BF recombinant HIV-1 strains.
The Journal of antimicrobial chemotherapy - 1 Jun 2020
Sánchez Daniela, Arazi Caillaud Solange, Zapiola Ines, Fernandez Giuliano Silvina, Bologna Rosa, Mangano Andrea, Aulicino Paula C
Abstract excerpt
BACKGROUND: Current knowledge on HIV-1 resistance to integrase inhibitors (INIs) is based mostly on subtype B strains. This contrasts with the increasing use of INIs in low- and middle-income countries, where non-B subtypes predominate. MATERIALS AND METHODS: HIV-1 drug resistance genotyping was performed in 30 HIV-1-infected individuals undergoing virological failure to raltegravir. Drug resistance mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.